[{"address1": "2625 Townsgate Road", "address2": "Suite 230", "city": "Westlake Village", "state": "CA", "zip": "91361", "country": "United States", "phone": "805 267 9889", "website": "https://www.genelux.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Zindrick J.D.", "age": 64, "title": "Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 570990, "exercisedValue": 0, "unexercisedValue": 11528577}, {"maxAge": 1, "name": "Ms. Lourie S. Zak", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 346195, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Caroline  Jewett", "age": 58, "title": "VP & Head of Quality", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 269264, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph  Cappello Ph.D.", "age": 66, "title": "Chief Technical Officer", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 213077, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean  Ryder J.D.", "age": 54, "title": "General Counsel & Corporate Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Yong  Yu Ph.D.", "age": 52, "title": "Senior Vice President of Clinical Development", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 242615, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Paul  Scigalla M.D., Ph.D.", "age": 78, "title": "Chief Medical Officer", "yearBorn": 1945, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ralph  Smalling B.Sc.", "age": 66, "title": "VP & Head of Regulatory Affairs", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.92, "open": 1.88, "dayLow": 1.85, "dayHigh": 1.99, "regularMarketPreviousClose": 1.92, "regularMarketOpen": 1.88, "regularMarketDayLow": 1.85, "regularMarketDayHigh": 1.99, "forwardPE": -1.8333333, "volume": 120694, "regularMarketVolume": 120694, "averageVolume": 277927, "averageVolume10days": 426050, "averageDailyVolume10Day": 426050, "bid": 1.96, "ask": 2.0, "bidSize": 200, "askSize": 200, "marketCap": 68016960, "fiftyTwoWeekLow": 1.71, "fiftyTwoWeekHigh": 35.15, "priceToSalesTrailing12Months": 8502.12, "fiftyDayAverage": 2.9752, "twoHundredDayAverage": 10.0056, "currency": "USD", "enterpriseValue": 35339544, "floatShares": 21478640, "sharesOutstanding": 34352000, "sharesShort": 1690240, "sharesShortPriorMonth": 2441940, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.049200002, "heldPercentInsiders": 0.17534, "heldPercentInstitutions": 0.17679001, "shortRatio": 4.35, "shortPercentOfFloat": 0.0584, "impliedSharesOutstanding": 34352000, "bookValue": 0.568, "priceToBook": 3.4859154, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -25783000, "trailingEps": -0.92, "forwardEps": -1.08, "enterpriseToRevenue": 4417.443, "enterpriseToEbitda": -1.393, "52WeekChange": -0.94018126, "SandP52WeekChange": 0.26253593, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "GNLX", "underlyingSymbol": "GNLX", "shortName": "Genelux Corporation", "longName": "Genelux Corporation", "firstTradeDateEpochUtc": 1674743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "818a2610-5027-31af-b56b-57304f2478db", "messageBoardId": "finmb_11172383", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.98, "targetHighPrice": 32.0, "targetLowPrice": 18.0, "targetMeanPrice": 23.5, "targetMedianPrice": 22.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 19627000, "totalCashPerShare": 0.739, "ebitda": -25371000, "totalDebt": 2371000, "quickRatio": 2.515, "currentRatio": 2.717, "totalRevenue": 8000, "debtToEquity": 15.719, "returnOnAssets": -0.82135004, "returnOnEquity": -2.90104, "freeCashflow": -11130000, "operatingCashflow": -20039000, "revenueGrowth": -0.953, "grossMargins": 1.0, "operatingMargins": -1014.375, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-08"}]